4.5 Review

Metal-based photosensitizers for photodynamic therapy: the future of multimodal oncology?

期刊

CURRENT OPINION IN CHEMICAL BIOLOGY
卷 56, 期 -, 页码 23-27

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2019.10.004

关键词

Bioinorganic chemistry; Medicinal inorganic chemistry; Metals in medicine; Photodynamic therapy; Photosensitizer

资金

  1. ERC Consolidator Grant PhotoMedMet [GA 681679]
  2. program Investissements d'Avenir
  3. ANR [ANR-10-IDEX-0001-02 PSL]
  4. University of North Carolina at Greensboro
  5. University of Texas at Arlington
  6. National Cancer Institute of the National Institutes of Health [R01CA222227]
  7. Theralase Technologies Inc. (Toronto, Ontario, Canada)
  8. NATIONAL CANCER INSTITUTE [R01CA222227] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Photodynamic therapy (PDT) is an approved medical technique to treat certain forms of cancer. It has been used to complement traditional anticancer modalities such as surgery, chemotherapy or radiotherapy, and in certain cases, to replace these treatments. One critical parameter of PDT is the photosensitizer (PS); historically, a purely organic macrocyclic tetrapyrrole-based structure. This short review surveys two recent clinical examples of metal complexes, namely TOOKAD (R)-Soluble and TLD-1433, which have ideal photophysical properties to act as PDT PSs. We highlight the important role played by the metal ions in the PS for PDT activity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据